ACE2 and COVID-19: While hypertension is one of the most common diseases in the general population, its coexistence with pulmonary COVID-19 has been vastly discussed because SARS-CoV-2 infiltration of human cells occurs via the angiotensin-converting enzyme 2 presented on the cell surface, and its expression is being modified with antihypertensive drugs [41,42].